33 results about "Gastrointestinal inflammation" patented technology

The invention discloses a composition for treating insomnia. Comprising probiotic compounds: lactobacillus plantarum, bifidobacterium lactis, lactobacillus crispatus, lactobacillus acidophilus, lactobacillus rhamnosus, bifidobacterium bifidum, lactobacillus reuteri, lactobacillus casei, lactobacillus bulgaricus, lactobacillus fermentum, lactobacillus gasseri, lactococcus lactis, bifidobacterium longum, lactobacillus salivarius, bifidobacterium breve, streptococcus thermophilus and lactobacillus paracasei; lactobacillus helveticus; and traditional Chinese medicine components and prebiotics. Probiotics are matched with traditional Chinese medicines with homology of medicine and food, and corresponding prebiotics are supplemented, so that the balance of intestinal flora can be adjusted and information transmission between intestines and cranial nerves can be promoted through the synergistic effect of the probiotics and the corresponding prebiotics, and then gastrointestinal inflammation, ulcer, helicobacter pylori infection, constipation and insomnia are treated or improved; and treating or improving spleen and stomach disharmony, liver qi stagnation, excessive heart fire, fire excess from yin deficiency, heart-kidney disharmony caused by emotion, pressure, diseases and the like, and insomnia caused by the symptoms.

The present invention is directed to orally administered compositions of topically acting corticosteroids for the treatment of inflammation of the gastrointestinal tracts such as eosinophilic esophagitis. The present invention also provides a method for treating conditions associated with inflammation of the gastrointestinal tract in an individual. The method comprises administering to an individual in need thereof a pharmaceutical composition of the present invention as orally disintegrating tablets comprising a topically active corticosteroid adsorbed onto a pharmaceutically acceptable carrier such as silicified microcrystalline cellulose.

The invention provides assays and methods for analyzing inflammatory disorders of the gastrointestinal (GI) tract. Provided in embodiments of the invention are host transcriptome markers and classifiers amenable for assessing and monitoring the existence, severity and location of inflammation associated with inflammatory bowel disease (IBD), Crohn's disease (CD) and Ulcerative colitis (UC). Further provided are improved protocols for processing and analyzing fecal samples, providing superior non-invasive means for evaluating GI inflammation.

The invention discloses a phagocytosis-resistant indigo engineering strain, which can sensitively respond to enteritis-related thiosulfate inflammatory factors, timely release a drug indigo to treat gastrointestinal inflammation, and release sfGFP signal molecules to assist in diagnosis and monitoring of diseases, and is very helpful for slowing down disease progression. In addition, through knockout of fhuA and trxA genes related to bacteriophage infection and knockin of an sspB-sspC-sspD-sspE gene cluster, the survival rate of the strain in the intestinal tract can be improved, and the treatment and diagnosis effects of the strain are improved.

Disclosed herein are methods of treating or preventing inflammatory diseases of the gastrointestinal (GI) tract by topical administration of a pharmaceutical composition containing a delayed release composition formulated for extended release of corticosteroids into GI tissue.

This disclosure provides a method of treating gastrointestinal inflammation such as inflammatory bowel disease (IBS) with a bacteriophage containing composition. The bacteriophage containing composition can be used as prebiotic supplementation and support of the gastrointestinal microflora. This disclosure relates to compositions that comprise one or more types of bacteriophage and methods of using such bacteriophages as a prebiotic to promote the growth of beneficial bacteria by decreasing harmful bacterial populations and releasing nutrients into the environment for good bacteria in the digestive system of an individual.

The invention discloses a novel nanocarbon material with conditioning and treating functions and a preparation method thereof, and belongs to the technical field of health food. According to the novel nano-carbon material, a biological nano-carbon material is organically combined with active magnesium and active silicon, so that a finished product is endowed with unique conditioning and treatment functions. The traditional Chinese medicine composition integrates multiple mechanisms such as sterilization and disinfection, immune enhancement, free radical removal and cell activation, not only has a direct treatment effect on oral inflammation, gastroenteritis, skin inflammation, cyst and the like, but also can fundamentally improve the sub-health state by regulating the acid-base balance of an organism, promoting metabolism and delaying senescence. The whole process is carried out in a 10000-grade clean environment at normal temperature and normal pressure, so that the operation process is simplified, the energy consumption and equipment requirements are reduced, the damage of extreme conditions such as high temperature and high pressure to the activity of the material can be effectively avoided, and the effect of each component is fully exerted.

The present invention relates to therapeutic compositions containing a hydrogel, in particular hydrogel particles, and optionally at least one pharmaceutically acceptable carrier for use in a method for treating inflammatory diseases in the gastrointestinal tract of a human or animal patient.

The invention discloses a cat and dog gastrointestinal inflammation alleviator containing plant extracts and application of the cat and dog gastrointestinal inflammation alleviator, and relates to the field of pet health. The alleviator is prepared by compounding a plant extract component, a micro-ecological component, a functional auxiliary component and a carrier raw material, plant active components are purified by adopting an ultrasonic-assisted ethanol gradient elution combined membrane separation technology, and the problem of antagonism of a plant extract and probiotics is solved through microcapsule embedding and step-by-step compounding. The sustained-release preparation is prepared by combining sustained-release preparation forming and palatability optimization technologies. The traditional Chinese medicine composition can synergistically achieve the effects of resisting inflammation, repairing gastrointestinal mucosa, regulating intestinal flora and quickly stopping diarrhea, is suitable for preventing and treating acute and chronic enterogastritis of cats and dogs, and is good in palatability, high in stability, free of obvious toxic and side effects and convenient to administrate.

The invention belongs to the technical field of special medical food, and relates to application of common turnip in products for inhibiting gastrointestinal tract helicobacter pylori. The common turnip extract has the function of treating or preventing helicobacter pylori infection, has a good improvement effect on prevention and inhibition of gastroenteritis caused by helicobacter pylori, remarkably improves the function of a digestive system, and can be used for preventing and treating the gastroenteritis caused by the helicobacter pylori and preventing and treating the gastroenteritis caused by the helicobacter pylori. And support is provided for developing novel dietary nutrition supplements, functional foods, special medical foods and pharmaceutical compositions for inhibiting helicobacter pylori. The invention further discloses a synergistic effect of a medicinal and edible composition formed by combining the common turnip extract with extracts of clove, codonopsis pilosula, hericium erinaceus, fructus amomi and the like on inhibition of helicobacter pylori, and a greater effect of inhibiting the activity of the helicobacter pylori can be achieved. The novel product for inhibiting helicobacter pylori developed by the invention has both safety and effectiveness, and has a very good application prospect.

The application discloses a preparation method of a gastrointestinal inflammation treating tablet, and steps of the method comprise the following steps: (1) preparing an extract solution of lotus leaves and red dates to obtain extract solution I; preparing an extract solution of eggshell membrane powder to obtain extract solution II; combining the extract solution I and the extract solution II, performing enzyme inactivation treatment, and concentrating the combined solution to a paste under reduced pressure to obtain an extract paste; (2) adding pueraria powder, threonine and tryptophan into the extract paste, and uniformly stirring the mixture after the addition is completed to obtain an auxiliary material; and (3) preparing a paste body, adding the auxiliary material, compressing the paste body into a tablet, and coating the tablet with sugar or film coating to obtain the tablet. The auxiliary material prepared by the method has good bacteriostasis, and has good inhibition effect on escherichia coli and staphylococcus aureus; after being added into the tablet, the auxiliary material can effectively improve the bactericidal and bacteriostatic effect of the tablet; meanwhile, the prepared tablet has low friability, so that the tablet is not prone to powder dropping, fragmentation and other phenomena during packaging, transportation and processing, and the qualified rate of the finished product is high.

The present invention relates to polymorphs of the hydrobromide salt of 5-{2-[({8-[(2,6-dimethylbenzyl)amino]-2,3-dimethylimidazo[1,2-a]pyridin-6-yl}carbonyl)-amino]ethoxy}-5-oxopentanoic acid (linaprazangrate), more specifically Form A, Form B, and Form C of the HBr salt of linaprazangrate. The present invention also relates to pharmaceutical compositions containing such polymorphs and to the use of these polymorphs in the treatment or prevention of gastrointestinal inflammatory or gastric acid-related diseases, particularly erosive gastroesophageal reflux disease (eGERD).

The present invention relates to a polymorph of the maleate salt of 5-{2-[({8-[(2,6-dimethylbenzyl)amino]-2,3-dimethylimidazo[1,2-a]pyridin-6-yl}carbonyl)-amino]ethoxy}-5-oxopentanoic acid (linaprazangrate), more particularly to linaprazangrate maleate Form 1. The present invention also relates to pharmaceutical compositions comprising such polymorph and to the use of this polymorph in the treatment or prevention of gastrointestinal inflammatory or gastric acid-related diseases, particularly erosive gastroesophageal reflux disease (eGERD).

The present invention relates to the field of the human gut microbiome, more particularly to its effect on health and disease. Provided herein are means and methods of classifying the gut microbiome based on qPCR data. The invention also provides methods to diagnose and treat or reduce the severity of gut flora dysbiosis as well as of gastro-intestinal inflammation and inflammation-associated disorders or conditions in a subject in need thereof.

A composition for young children comprising glycosphingolipids. The present invention relates to a composition comprising one or more glycosphingolipids, to a nutritional formula for children comprising said composition, to the use of said composition for supporting healthy growth and development of young children, in particular infants, and for dietary management of symptoms related to inflammation of the gastrointestinal tract system of said young children. In particular, the present invention relates to a composition comprising one or more compounds of formula (1) or salts thereof: wherein R1 is a C13-C17 alkyl chain; r2 is a C15-C19 alkyl chain; and R3 is a glycosyl moiety selected from Neu5Ac [alpha] 2-3-Gal [beta] 1-4-Glc [beta] 1-or Neu5Ac [alpha] 2-8-Neu5Ac [alpha] 2-3-Gal [beta] 1-4-Glc [beta] 1-. Children's nutritional formulas comprising the composition are also provided.

This invention discloses a maltol-iron-quercetin eutectic, which exhibits characteristic diffraction peaks at diffraction angles of approximately 8.6±0.2°, 11.1±0.2°, 12.1±0.2°, 15.0±0.2°, 20.1±0.2°, 22.9±0.2°, 23.4±0.2°, 25.0±0.2°, and 26.4±0.2° in X-ray powder diffraction patterns obtained using Cu-Kα radiation. The maltol-iron-quercetin eutectic of this invention exhibits good stability, showing no crystal transformation for at least 60 days under accelerated conditions (40°C, 75% RH). By introducing the cocrystallized ligand quercetin, the maltol iron-quercetin cocrystallization has relatively low solubility and a slower dissolution rate, which can ensure a more stable and sustained release rate of the drug in vivo, avoid short-term drug concentration peaks, and reduce the side effects of maltol iron gastrointestinal inflammation.

Methods and systems one or more for performing intra-luminal ultraviolet therapy for treating and / or ameliorating a gastrointestinal tract inflammation and / or infection are provided. In one example, a light delivery catheter may include a light emitting portion and non-illuminating portion, wherein the light emitting portion may include one or more UV transparent balloons. In some examples, the UV light source is configured to emit narrow-band light having wavelengths in a range between 335 nm and 349 nm.

The invention provides a gastrointestinal tract adhesion type retention tablet and a preparation method thereof. The retention tablet is prepared from the following components in parts by mass: 0.01-1 part of a nano-drug compound, 2-3.5 parts of a filler, 1.5-2.5 parts of a disintegrating agent, 0.7-1.5 parts of an adhesive mixture and 0.3-0.9 part of carbonate coated Fe3O4 microspheres. Wherein the nano-drug compound is a compound of a gastroenteritis treatment drug wrapped by PLGA and DHA; the adhesive mixture is prepared by mixing an adhesive and polydopamine according to the ratio of 1: 1; the carbonate coated Fe3O4 microspheres have the characteristics of magnetic targeting and sonokinetic response through a Fe3O4 coated sonokinetic response agent. The preparation method comprises a direct tabletting method or an indirect tabletting method, and the indirect tabletting method comprises wet granulation and fluidized bed granulation and is realized by controlling pressure and process parameters. The retention tablet has the characteristics of intragastric adhesion, magnetic targeting and sonokinetic response, so that a medicinal preparation is firmly attached to the surface of gastrointestinal mucosa, and the gastrointestinal tract retention time of the medicine is prolonged.

The present disclosure relates to a method of treating a gastrointestinal (GI) inflammatory disease or condition in a subject in need thereof, comprising topically administering to the subject a pharmaceutical formulation comprising a therapeutically effective amount of a JAK inhibitor, said topical administration comprising orally administering an ingestible device to the subject, said device containing the pharmaceutical formulation, and releasing the pharmaceutical formulation from the device (a) to a section or subsection of the subject's GI tract containing one or more inflammatory disease sites; or (b) proximal to a section or subsection of the subject's GI tract containing one or more inflammatory disease sites, wherein the onset of the pharmaceutical formulation release occurs before the ingestible device reaches the disease site.

The invention discloses an enterogastritis-related convulsion prediction method and system, and the method comprises the steps: obtaining the historical clinical data of a patient, screening the index data of the occurrence of enterogastritis-related convulsion from the historical clinical data, carrying out the data preprocessing of the collected index data, obtaining multi-modal clinical data, taking the multi-modal clinical data as an input feature, and carrying out the prediction of the enterogastritis-related convulsion. The method comprises the following steps: taking whether a patient has convulsion within a preset time as a prediction target, training to obtain a corresponding convulsion prediction model, inputting clinical data of a to-be-assessed patient into the convulsion prediction model obtained by training to output a convulsion occurrence risk probability value, determining a risk level corresponding to the convulsion occurrence risk probability value, and comprehensively analyzing various factors to determine the risk level of the to-be-assessed patient. The risk of convulsion possibly occurring in the gastroenteritis patient is predicted in advance, so that corresponding prevention measures can be taken in time, the occurrence rate of convulsion is reduced, and the treatment effect and life quality of the patient are improved.

The present invention relates to a composition for use in the prevention or treatment of gastrointestinal infections / inflammation in infants or young children. The present invention relates to a nutritional composition comprising at least one fucosylated oligosaccharide and at least one N-acetylated oligosaccharide in specific proportions for use in the prevention and / or treatment of gastrointestinal infections and / or gastroenteritis in infants or young children.

The present invention relates to a polymorphic form of a maleate of 5-{2-[({8-[(2, 6-dimethylbenzyl) amino]-2, 3-dimethylimidazo [1, 2-a] pyridin-6-yl} carbonyl)-amino] ethoxy}-5-oxovaleric acid (linaraben glutarate), and more particularly to Form 1 of a maleate of linaraben glutarate. The invention also relates to a pharmaceutical composition containing the polymorphic substance, and application of the polymorphic substance in treatment or prevention of gastrointestinal inflammatory diseases or gastric acid related diseases (especially erosive gastroesophageal reflux disease, eGERD).

The invention relates to the technical field of biology, and particularly discloses a biomarker combination for digestive tract inflammation and application thereof.The biomarker combination comprises the content of taurocholic acid sodium TLCA and the relative expression quantity of baiB, baiE, baiCD and baiG genes in a bai gene family, host metabolite (TLCA) is combined with the expression level of a flora functional gene (bai gene), and the content of the TLCA is increased; a brand-new and efficient biomarker combination is constructed, and the combination is high in intestinal inflammation judgment accuracy and is remarkably superior to a traditional method depending on a single index or a macroscopic flora structure, and the probability of false positive and false negative is effectively reduced.

To provide methods and compositions useful for treatment of pervasive developmental disorders.SOLUTION: The treatment includes the use of fibroblasts, modified fibroblasts, and derivatives thereof for reduction of neuroinflammation and / or gastrointestinal inflammation in a patient in need of treatment, such as having a pervasive developmental disorder. Fibroblasts, modified fibroblasts, and derivatives thereof may be administered at a frequency and concentration sufficient to reduce interleukin-17 production in the gut of patients with autism spectrum disorder.SELECTED DRAWING: Figure 1

The disclosure relates to therapeutic proteins and pharmaceutical compositions comprising said proteins, which have utility in treating various human diseases. In particular aspects, the disclosed therapeutic proteins are useful for treating human gastrointestinal inflammatory diseases and gastrointestinal conditions associated with decreased epithelial cell barrier function or integrity. Further, the disclosed therapeutic proteins are useful for treating human inflammatory bowel disease, including inter alia, Crohn's disease and ulcerative colitis.

The invention provides a composition for regulating gastrointestinal functions and application thereof. On the first aspect, the invention provides the composition for regulating the gastrointestinal function. The composition comprises 2-50 parts by mass of a pericarpium citri reticulatae extract and 2-50 parts by mass of a poria cocos extract; the mass ratio of the pericarpium citri reticulatae extract to the poria cocos extract is 1: (1-2). According to the composition provided by the invention, the synergistic interaction effect of all the components is realized through reasonable low-dose proportioning, and the composition is beneficial to promoting gastrointestinal peristalsis, improving gastrointestinal inflammation, relieving dyspepsia and repairing gastrointestinal mucosal lesion, especially promoting gastrointestinal peristalsis and eliminating gastrointestinal inflammation; moreover, the composition provided by the invention is derived from medicinal and edible substances and other plant extracts capable of being used in food, has the characteristics of high safety, small side effect, strong effect, good taste and flavor and the like, and can play a role in regulating the gastrointestinal function to the greatest extent by adding a relatively low dosage of the composition.

The present invention is directed to orally administered corticosteroid compositions. The present invention also provides a method for treating a condition associated with inflammation of the gastrointestinal tract in an individual. The method comprises administering to an individual in need thereof a pharmaceutical composition of the present invention.

The invention provides assays and methods for analyzing inflammatory disorders of the gastrointestinal (GI) tract. Provided in embodiments of the invention are host transcriptome markers and classifiers amenable for assessing and monitoring the existence, severity and location of inflammation associated with inflammatory bowel disease (IBD), Crohn's disease (CD) and Ulcerative colitis (UC). Further provided are improved protocols for processing and analyzing fecal samples, providing superior non-invasive means for evaluating GI inflammation.

The rapid development of tumor molecular targeted drugs and immunotherapy promotes the progress of tumor treatment field, but the treatment means of related adverse reactions is very single, the application discloses a kind of traditional Chinese medicine composition and preparation method for preventing and treating new generation of tumor targeted and immunotherapy related adverse reactions.The composition includes the following mass parts of traditional Chinese medicinal materials: 3-20 parts of radix astragali, 3-18 parts of radix rehmanniae, 3-15 parts of radix lithospermi, 3-20 parts of old snake tongue grass, 3-20 parts of white milk vetch, 3-18 parts of old heron grass, 3-12 parts of gallnut, 3-20 parts of fried elaterium, 3-10 parts of raw licorice.The traditional Chinese medicine composition has the effects of nourishing yin and benefiting qi, promoting blood circulation to expel wind, detoxifying and removing turbidity, and is good for preventing and treating skin rash, gastrointestinal inflammation and diarrhea, hypothyroidism, proteinuria, hypertension, pneumonia, myocarditis and the like.The preparation method is decoction, granules, pills and capsule preparations.The application is simple, economical and effective, has no toxic side effects, and is helpful to prolong the tolerance period of targeted and immunotherapy and improve the survival quality of patients.

The invention provides a composition for protecting gastric mucosa, relieving gastroenteritis and promoting peristalsis and application of the composition, and particularly relates to a composition which comprises hericium erinaceus or an extract of the hericium erinaceus, Chinese yam or an extract of the Chinese yam and rhizoma zingiberis or an extract of the rhizoma zingiberis. The composition can remarkably improve gastrointestinal motility, repair gastrointestinal mucosa injury and relieve gastrointestinal inflammation. The liquid dairy product containing the composition is harmonious in taste, unique in flavor and high in acceptability of audiences.